NasdaqGM:CRSPBiotechs
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Momentum And Gene Editing Pipeline Progress
Growing physician adoption and patient referrals for Casgevy are putting CRISPR Therapeutics (CRSP) back in focus, as the company reports a narrower Q1 2026 loss and highlights multiple gene editing milestones ahead.
See our latest analysis for CRISPR Therapeutics.
CRISPR Therapeutics’ recent Q1 update and growing Casgevy uptake appear to be feeding into short term momentum, with a 1 day share price return of 5.32% and a 7 day share price return of 12.99%. However, the 90 day share price...